sabcs 2019 - oncoletter · lcm (34%) o nodes tumor and/or pgr.ve (64%) pertuzumab er.ve and/or...

12

SABCS 2019

Upload: others

Post on 22-Jun-2020

0 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 2: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 3: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 4: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 5: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 6: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 7: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 8: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 9: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 10: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 11: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 12: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Pertuzumab in combination with trastuzumab and docetaxel

Pertuzumab and trastuzumab: the rationale way to synergy...Pertuzumab and trastuzumab: the rationale way to synergy Sandrine richard1, Frédéric Selle1, Jean-Pierre lotz1,2, ahmed

09h00 - neoadjuvant Piergabis · 2014. 11. 25. · NeoSphere:designdel’étude THP(n=107) docetaxel+ trastuzumab+ pertuzumab HP(n=107) trastuzumab+ pertuzumab TP(n=96) docetaxel+

Pertuzumab Monograph - Pharmacy Benefits … Cancer (MBC) (CLEOPATRA) that compared placebo/trastuzumab/doceta FDA-approval of pertuzumab in MBC was supported by the phase 3 trial

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive

Neue Wege der Her2-zielgerichteten Therapie Aphinity-Studie/ … · Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs. Pertuzumab + Trastuzumab

Presentazione standard di PowerPoint - Acute medicine€¦ · •Interventional radiology (mechanical fragmentation, thrombosuction) ... Comparator drug Placebo Placebo Warfarin Placebo

Perjeta (pertuzumab) Data Sheet (DS) - Medsafe Home · PDF file · 2017-07-04Perjeta DS 161125 2 The PK results of pertuzumab in the NEOSPHERE study were consistent with the predictions

Pertuzumab, INN-perjeta

Perjeta, INN-pertuzumab

Placebo presentation

pan-Canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab … · CLEOPATRA was an industry-funded multicentre, double-blind, placebo-controlled randomized controlled

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment

Phesgo; INN-pertuzumab / trastuzumab

A13-10 - Pertuzumab - Nutzenbewertung gemäß § 35a SGB V

Enfermedad con sobreexpresión de HER-2 neu · 2017. 5. 31. · – Pertuzumab/placebo: 840 mg loading → 420 mg maintenance – Trastuzumab: 8 mg/kg loading → 6 mg/kg maintenance

Pertuzumab and trastuzumab: the rationale way to synergy

PRACTICE CHANGING STUDIES IN GASTROINTESTINAL … · safety, PK, QoL Treatment arm A Treatment arm B Trastuzumab + pertuzumab 840 mg IV q3w Trastuzumab + placebo IV q3w • Geographical

Pertuzumab and trastuzumab: the rationale way to synergy · growth (Agus et al. 2002, Cho et al. 2003, Yarden and Sliwkowski 2001, Harari and Yarden 2000). Pertuzumab can inhibit

Placebo i Placebo Efekat

Trastuzumab en combinación con pertuzumab en cáncer de mama

DSC 5266 - Willkommen bei oncoletter - Oncoletter, …web.oncoletter.ch/files/cto_layout/Kongressdateien/ASC… · · 2014-01-18Metastatic Gastric or Gastroesophageal Junction (GEJ)

FDA Approval Summary: Pertuzumab for adjuvant treatment …...placebo 3.7%). Almost all diarrhea serious adverse events (SAEs) required hospitalization (56 patients in the pertuzumab

Tabletas Placebo

TRATAMIENTO NEOADYUVANTE CON PERTUZUMAB EN … · (pertuzumab y trastuzumab) en el tratamiento neadyuvante del cáncer de mama HER2+ TRATAMIENTO NEOADYUVANTE CON PERTUZUMAB EN CANCER

Pertuzumab - SEOM: Sociedad Española de Oncología Médica · Estudio CLEOPATRA, estudio pivotal de la eficacia y seguridad de Pertuzumab en combinación con Trastuzumab y

The Placebo Effect. Placebo Effect Introduction sFTgirKXHk 4 mins

Ado-Trastuzumab Emtansine (Kadcyla®) · PDF filetrastuzumab emtansine combined with pertuzumab vs. ado-trastuzumab emtansine plus pertuzumab placebo vs. trastuzumab plus taxane as

IQWiG Reports – Commission No. A13-10 Pertuzumab – Benefit ...€¦ · Extract of dossier assessment A13-10 Version 1.0 Pertuzumab – Benefit assessment acc. to § 35a Social

Pertuzumab and trastuzumab: the rationale way to · PDF fileAn Acad Bras Cienc (2016) 88 (1 Suppl.) PERTUZUMAB-TRASTUZUMAB COMBINATION 567 through homo- or heterotypic interactions